先后于2012-2014年在美国哈佛大学美高梅Dana Farber Cancer Institute做访问学生和2019-2021年在加拿大多伦多大学Princess Margaret Cancer Research Center做博士后研究,获国家留学基金委2019年公派博士后项目留学奖学金。入选包括2022年上海市浦江人才(D类)人才计划(上海市白玉兰人才计划浦江项目)、2021年上海市“医苑新星”青年医学人才培养资助计划、2016年美高梅青年优秀人才培养行动计划、2019年上海市肺科医院“梦想导师”优秀青年人才计划等人才计划。以项目负责人获得国家自然科学基金、省部级、局级等课题共10余项。以第一作者(含共一)或通讯作者(含共通)在《Nature Genetics,影响因子31.7》、《美国国家科学院学报》(PNAS,影响因子11.1)、《Discover Oncology》、《Frontiers in Bioscience-Landmarks》等国际知名学术期刊上发表SCI论文20余篇,参与发表《Nature Methods》、《Nature Cell Biology》、《Nature Cancer》等Nature大子刊,总影响因子超过100。多次荣获优秀员工、优秀党员等荣誉称号。以主要完成人员获得第十二届东方检验医学论坛优秀论文一等奖。主编《肺结核防治小课堂》著作。授权发明专利1项。
主持项目:
1. 美高梅青年优秀人才计划项目,肺腺癌中EGFR基因靶向药物吉非替尼耐药基因的筛选和作用机制研究,项目批准号kx0151120171864,2017.01-2018.12 ,5万,主持
2. 美高梅国自然培育计划,基于CRISPR-Cas9技术对肺腺癌中EGFR基因靶向药物奥西替尼耐药基因的筛选及作用机制研究, 项目批准号22120170107,2017.09-2018.12,5万,主持
3. 国家自然基金青年项目,YAP1和NEK2在第三代EGFR-TKI耐药中的功能和机制研究,项目批准号31801111,201901-202112,27万,主持
4. 上海市肺科医院梦想导师优秀青年人才计划,基于MeRIP-seq技术对肺癌表观转录组谱分析,项目批准号fkyq1910,201907-202206, 20万,主持
5. 美高梅国自然培育计划,转录因子KLF4通过调控KRT19表达影响非小细胞肺癌细胞周期的作用和机制研究, 2019.09-2020.12,3万,主持
6. 上海市卫健委,上海市“医苑新星”青年医学人才培养资助计划,项目号 202208-2274,202201-202412,10万元,在研,主持
7. 上海市浦江人才D类,体内CRISPR筛选鉴定MEN1在调节肿瘤和微环境互作中的双重功能,项目编号22PJD063,2022.10-2024.09,30万,在研,主持
8. 综合运用整合多维组学数据研究手段和体内CRISPR筛选方法来干预和治疗实体瘤,上海市肺科医院优青培育,课题编号fkzr2302,5万元,2023.01-2023.12,主持
9. 科技部国家重点研发计划“地球观测与导航”重点专项青年科学家项目,道路交通污染精细时空尺度监测评估技术及应用,300万,项目编号:2023YFB3906900,参与任务4:考虑人群时空轨迹的污染暴露风险与防控决策效果评估,参与单位的项目负责人。
10. 癌症转录调控和肿瘤免疫治疗,上海市肺科医院国家优青培育计划,课题编号fkzr2405,5万元,2024.01-2024.12,主持
参与项目:
1. 肠出血型大肠埃希菌VI型分泌系统核心跨膜结构组分的鉴定及组装研究,31800122,青年科学基金项目,201901-202112, 25万
2. 构建癌症中基于ceRNA机制的长非编码RNA调控网络,31329003,海外及港澳学者合作研究基金,201401-201712,200万
代表性论文:
1. Yin Liu, Ke Zhou, Xin-Yun Li, Shu-Hong Zhao and Jian-Hua Cao. Expression Profiling of Myoz1 Gene in Porcine Tissue and C2C12 Cells. Journal of Animal and Veterinary Advances 10(15): 1917-1921, 2011
2. H.H He, C.A. Meyer, S.S. Hu, M-W Chen, C. Zang, Yin Liu, P.K. Rao, T. Fei, H. Xu, H. Long, X.S. Liu M. Brown. Refined DNase-seq protocol and data analysis reveals intrinsic bias in transcription factor footprint identification. Nature methods 11(10), 73-80, 2013 (Q1, IF: 23.565)
3. Wang H, Zheng X, Fei T, Wang J, Li X, Liu Y, Zhang F. Towards pathway-centric cancer therapies via pharmacogenomic profiling analysis of ERK signalling pathway. Clin Transl Med, 2015, 4: 66. (Q1, IF: 10.6)
4. Yin Liu, Teng Fei, Xiaoqi Zheng, Myles Brown, Peng Zhang, X.Shirley Liu, Haiyun Wang. An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine. Sci. Rep. 6, 22120; doi: 10.1038/srep22120 (2016). (Q2, IF: 5.228).
5. Liu Y, Chen S, Wang S, Soares F, Fischer M, Meng F, Du Z, Lin C, Meyer C, DeCaprio JA, Brown M, Liu XS, He HH. Transcriptional landscape of the human cell cycle. Proc Natl Acad Sci U S A, 2017, 114: 3473-3478. (Q1, IF: 11.1).
6. Zheng R, Li Z, He F, Liu H, Chen J, Chen J, Xie X, Zhou J, Chen H, Wu X, Wu J, Chen B, Liu Y, Cui H, Fan L, Sha W, Liu Y, Wang J, Huang X, Zhang L, Xu F, Wang J, Feng Y, Qin L, Yang H, Liu Z, Cui Z, Liu F, Chen X, Gao S, Sun S, Shi Y, Ge B. Genome-wide association study identifies two risk loci for tuberculosis in Han Chinese. Nat Commun 2018;9(1):4072. (Q1, IF: 12.353).
7. Wu X, Yang J, Tan G, Liu H, Liu Y, Guo Y, Gao R, Wan B, Yu F. Drug Resistance Characteristics of Mycobacterium tuberculosis Isolates From Patients With Tuberculosis to 12 Antituberculous Drugs in China. Front Cell Infect Microbiol 2019;9:345. (Q1, IF: 3.518).
8. Li, Z., B. Wang, S. Gu, P. Jiang, A. Sahu, C. H. Chen, T. Han, S. Shi, X. Wang, N. Traugh, H. Liu, Y. Liu, Q. Wu, M. Brown, T. Xiao, G. M. Boland and X. Shirley Liu (2020). "CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma." Genomics Proteomics Bioinformatics 18(1): 26-40. (Q1, IF: 7.150).
9. Xingwei Cao, Qing Zhan, Yinjuan Guo, Jinghui Yang, Yin Liu, Baoshan Wan, Xiaocui Wu, Qiaoshi Zhong, Yaping Hang, Yanhui Chen, Yanping Xiao, Fangyou Yu, Longhua Hu. Genotypic Characterization of katG, inhA, and ahpC in Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates in Shanghai, China. Jundishapur Journal of Microbiology. Ahvaz Vol. 12, Iss. 11, (Nov 2019): 1-6. DOI:10.5812/jjm.95713.
10. Guo Y, Cao X, Yu J, Zhan Q, Yang J, Wu X, Wan B, Liu Y, Yu F. Antimicrobial Susceptibility of Mycobacterium abscessus Complex Clinical Isolates from a Chinese Tertiary Hospital. Infect Drug Resist 2020; 13: 2001-2010. (Q2, IF: 3.9)
11. Guo Y, Cao X, Yang J, Wu X, Liu Y, Wan B, et al. Rifampin-resistance-associated mutations in the rifampin-resistance-determining region of the rpoB gene of Mycobacterium tuberculosis clinical isolates in Shanghai, PR China. J Med Microbiol. 2021. doi: 10.1099/jmm.0.001317. PubMed PMID: 33507146. (Q3, IF: 3.0)
12. Chen S, Zhu G, Yang Y, Wang F, Xiao YT, Zhang N, Bian X, Zhu Y, Yu Y, Liu F, Dong K, Mariscal J, Liu Y, Soares F, Loo Yau H, Zhang B, Chen W, Wang C, Chen D, Guo Q, Yi Z, Liu M, Fraser M, De Carvalho DD, Boutros PC, Di Vizio D, Jiang Z, van der Kwast T, Berlin A, Wu S, Wang J, He HH, Ren S. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol. 2021;23(1):87-98. doi: 10.1038/s41556-020-00613-6. PubMed PMID: 33420488. (Q1, IF: 20.042)
13. Morel KL, Sheahan AV, Burkhart DL, Baca SC, Boufaied N, Liu Y, et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer 2021, 2(4): 444-456. (Q1, IF: 23.013)
14. Guo YE, Liu Y, Zhang W, Luo H, Shu P, Chen G, Li Y. The clinicopathological characteristics, prognosis and immune microenvironment mapping in MSI-H/MMR-D endometrial carcinomas. Discov Oncol. 2022 Mar 3;13(1):12. doi: 10.1007/s12672-022-00466-5. PMID: 35239036; PMCID: PMC8894509. (Q2, IF: 3.8)
15. Zhong C, Guo YE, Yang Q, Song Y, Wang T, Cai B, Chen H, Du H, Wan J, Liu Y, Li Y, Wan X. Single-cell transcriptome analysis of small cell neuroendocrine tumor of the endometrium reveals ISL1 as a potential biomarker for diagnosis and treatment. Front Biosci (Landmark Ed). 2024 Mar 13;29(3):100. doi: 10.31083/j.fbl2903100. PMID: 38538277. (Q3, IF: 3.1)
16. Peiran Su, Yin Liu, Yibo Xue, Yong Zeng, Hansen He. In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor microenvironment interactions. Nature Genetics (Q1, IF: 31.7, accepted).
17. 许敏殷,刘银,刘丽蓉,γ干扰素释放试验联合IL-6检测对活动性肺结核的诊断价值。中国现代医学杂志, 2020,30(10):18-21。
18. 周蓓烨,李明才,刘银。Livin、Caspase-3和Bcl-2在非小细胞肺癌中的表达及意义。当代医药论丛, 2022,20(12):108-111。
19. 周蓓烨,王芳,刘银。安罗替尼联合信迪利单抗对晚期非小细胞肺癌的临床疗效分析,中国现代医学杂志,Vol. 32 No.23。
专利:
TREATMENT OF CANCER WITH MENIN INHIBITORS AND IMMUNO-ONCOLOGY AGENTS